15:54 , Nov 16, 2018 |  BC Week In Review  |  Financial News

Kymera raises $65M series B

Protein degradation company Kymera Therapeutics LLC (Cambridge, Mass.) closed an untranched $65 million series B round on Nov. 13 to bring its lead program into the clinic. Kymera is developing heterobifunctional molecules that bind to...
16:25 , Nov 13, 2018 |  BioCentury  |  Finance

Kymera’s degradation toolbox

As the protein degradation space continues to gain traction, Kymera Therapeutics LLC has attracted interest from investors to the tune of $65 million to bring its first program to the clinic. 6 Dimensions Capital, Bessemer...
12:03 , Nov 13, 2018 |  BC Extra  |  Financial News

Kymera raises $65M series B

Protein degradation company Kymera Therapeutics LLC (Cambridge, Mass.) closed an untranched $65 million series B round to bring its lead program into the clinic. Kymera is developing heterobifunctional molecules that bind to both an E3...
00:18 , Dec 20, 2017 |  BC Extra  |  Company News

Management tracks: Intellia, Spectrum

Gene editing company Intellia Therapeutics Inc. (NASDAQ:NTLA) said CEO Nessan Bermingham will resign, effective Jan. 1. EVP of R&D John Leonard will succeed Bermingham. Hematology and cancer company Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) said CEO Rajesh...
03:08 , Sep 23, 2017 |  BioCentury  |  Emerging Company Profile

Selective suppression

Kezar Life Sciences Inc. is targeting the immunoproteasome to selectively suppress the hyperactive immune cells that drive autoimmunity. The company expects its biologics to have the rapid onset and broad activity of steroids, but without...
21:28 , Jul 28, 2017 |  BC Week In Review  |  Financial News

Kezar raises $50M in series B

On July 25, autoimmune company Kezar Life Sciences Inc. (South San Francisco, Calif.) raised $50 million in an oversubscribed series B round led by Cormorant Asset Management and Morningside Ventures. New investors Cowen, Pappas Ventures,...
18:56 , Jul 25, 2017 |  BC Extra  |  Financial News

Kezar raises $50M in series B round

Autoimmune company Kezar Life Sciences Inc. (South San Francisco, Calif.) raised $50 million in an oversubscribed series B round led by Cormorant Asset Management and Morningside Ventures. New investors Cowen, Pappas Ventures, Qiming Venture Partners...
18:24 , May 19, 2017 |  BioCentury  |  Finance

Back door listing

Allowing management to focus on drug development while avoiding the uncertainty of the IPO process is prompting a who’s who of biotech investors to take synthetic biology company Synlogic Inc. public via a back door...
00:22 , May 19, 2017 |  BC Week In Review  |  Company News

Synlogic finds public route via Mirna, raises $42M

Synthetic biology company Synlogic Inc. (Cambridge, Mass.) will become a publicly traded entity via a reverse merger with Mirna Therapeutics Inc. (NASDAQ:MIRN). The combined company will keep Synlogic's name and develop that company's programs, including...
19:59 , May 16, 2017 |  BC Extra  |  Financial News

Synlogic finds public route, raises $42M

Synthetic biology company Synlogic Inc. (Cambridge, Mass.) will become a publicly traded entity via a reverse merger with Mirna Therapeutics Inc. (NASDAQ:MIRN). The combined company will keep Synlogic's name and develop that company's programs, including...